Updated results of STEPP, a phase 2, open-label study of pre-emptive versus reactive skin toxicity treatment in metastatic colorectal cancer (MCRC) patients receiving panitumumab plus folfiri or irinotecan-only chemotherapy as second-line treatment
暂无分享,去创建一个
M. Lacouture | E. Mitchell | M. Yassine | B. Piperdi | H. Shearer | Nicholas Lannofti | M. Pillai | Xu Feng